303 related articles for article (PubMed ID: 31330122)
1. Non-cell autonomous mechanism of Parkinson's disease pathology caused by G2019S LRRK2 mutation in Ashkenazi Jewish patient: Single cell analysis.
Kim J; Daadi MM
Brain Res; 2019 Nov; 1722():146342. PubMed ID: 31330122
[TBL] [Abstract][Full Text] [Related]
2.
Kim J; Daadi EW; Daadi ES; Oh T; Deleidi M; Daadi MM
Cells; 2023 Oct; 12(21):. PubMed ID: 37947628
[TBL] [Abstract][Full Text] [Related]
3. The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.
Thaler A; Ash E; Gan-Or Z; Orr-Urtreger A; Giladi N
J Neural Transm (Vienna); 2009 Nov; 116(11):1473-82. PubMed ID: 19756366
[TBL] [Abstract][Full Text] [Related]
4. Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry.
Lee AJ; Wang Y; Alcalay RN; Mejia-Santana H; Saunders-Pullman R; Bressman S; Corvol JC; Brice A; Lesage S; Mangone G; Tolosa E; Pont-Sunyer C; Vilas D; Schüle B; Kausar F; Foroud T; Berg D; Brockmann K; Goldwurm S; Siri C; Asselta R; Ruiz-Martinez J; Mondragón E; Marras C; Ghate T; Giladi N; Mirelman A; Marder K;
Mov Disord; 2017 Oct; 32(10):1432-1438. PubMed ID: 28639421
[TBL] [Abstract][Full Text] [Related]
5. In Vitro Modeling of Leucine-Rich Repeat Kinase 2 G2019S-Mediated Parkinson's Disease Pathology.
Vermilyea SC; Emborg ME
Stem Cells Dev; 2018 Jul; 27(14):960-967. PubMed ID: 29402177
[TBL] [Abstract][Full Text] [Related]
6. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?
Orr-Urtreger A; Shifrin C; Rozovski U; Rosner S; Bercovich D; Gurevich T; Yagev-More H; Bar-Shira A; Giladi N
Neurology; 2007 Oct; 69(16):1595-602. PubMed ID: 17938369
[TBL] [Abstract][Full Text] [Related]
7. The Parkinson's-disease-associated mutation LRRK2-G2019S alters dopaminergic differentiation dynamics via NR2F1.
Walter J; Bolognin S; Poovathingal SK; Magni S; Gérard D; Antony PMA; Nickels SL; Salamanca L; Berger E; Smits LM; Grzyb K; Perfeito R; Hoel F; Qing X; Ohnmacht J; Bertacchi M; Jarazo J; Ignac T; Monzel AS; Gonzalez-Cano L; Krüger R; Sauter T; Studer M; de Almeida LP; Tronstad KJ; Sinkkonen L; Skupin A; Schwamborn JC
Cell Rep; 2021 Oct; 37(3):109864. PubMed ID: 34686322
[TBL] [Abstract][Full Text] [Related]
8. The LRRK2 G2019S mutation in a series of Argentinean patients with Parkinson's disease: clinical and demographic characteristics.
Gatto EM; Parisi V; Converso DP; Poderoso JJ; Carreras MC; Martí-Massó JF; Paisán-Ruiz C
Neurosci Lett; 2013 Mar; 537():1-5. PubMed ID: 23340200
[TBL] [Abstract][Full Text] [Related]
9. LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation.
Zhao Y; Keshiya S; Perera G; Schramko L; Halliday GM; Dzamko N
Neurobiol Dis; 2020 Oct; 144():105049. PubMed ID: 32800998
[TBL] [Abstract][Full Text] [Related]
10. In Vitro CRISPR/Cas9-Directed Gene Editing to Model LRRK2 G2019S Parkinson's Disease in Common Marmosets.
Vermilyea SC; Babinski A; Tran N; To S; Guthrie S; Kluss JH; Schmidt JK; Wiepz GJ; Meyer MG; Murphy ME; Cookson MR; Emborg ME; Golos TG
Sci Rep; 2020 Feb; 10(1):3447. PubMed ID: 32103062
[TBL] [Abstract][Full Text] [Related]
11. Distinctive genomic signature of neural and intestinal organoids from familial Parkinson's disease patient-derived induced pluripotent stem cells.
Son MY; Sim H; Son YS; Jung KB; Lee MO; Oh JH; Chung SK; Jung CR; Kim J
Neuropathol Appl Neurobiol; 2017 Dec; 43(7):584-603. PubMed ID: 28235153
[TBL] [Abstract][Full Text] [Related]
12. LRRK2 modifies α-syn pathology and spread in mouse models and human neurons.
Bieri G; Brahic M; Bousset L; Couthouis J; Kramer NJ; Ma R; Nakayama L; Monbureau M; Defensor E; Schüle B; Shamloo M; Melki R; Gitler AD
Acta Neuropathol; 2019 Jun; 137(6):961-980. PubMed ID: 30927072
[TBL] [Abstract][Full Text] [Related]
13. In vitro genome editing rescues parkinsonism phenotypes in induced pluripotent stem cells-derived dopaminergic neurons carrying LRRK2 p.G2019S mutation.
Chang KH; Huang CY; Ou-Yang CH; Ho CH; Lin HY; Hsu CL; Chen YT; Chou YC; Chen YJ; Chen Y; Lin JL; Wang JK; Lin PW; Lin YR; Lin MH; Tseng CK; Lin CH
Stem Cell Res Ther; 2021 Sep; 12(1):508. PubMed ID: 34551822
[TBL] [Abstract][Full Text] [Related]
14. Impaired dopamine D3 and nicotinic acetylcholine receptor membrane localization in iPSCs-derived dopaminergic neurons from two Parkinson's disease patients carrying the LRRK2 G2019S mutation.
Bono F; Mutti V; Devoto P; Bolognin S; Schwamborn JC; Missale C; Fiorentini C
Neurobiol Aging; 2021 Mar; 99():65-78. PubMed ID: 33422895
[TBL] [Abstract][Full Text] [Related]
15. Motor and non-motor features of Parkinson's disease in LRRK2 G2019S carriers versus matched controls.
Gunzler SA; Riley DE; Chen SG; Tatsuoka CM; Johnson WM; Mieyal JJ; Walter EM; Whitney CM; Feng IJ; Owusu-Dapaah H; Mittal SO; Wilson-Delfosse AL
J Neurol Sci; 2018 May; 388():203-207. PubMed ID: 29627023
[TBL] [Abstract][Full Text] [Related]
16. Progressive degeneration of human neural stem cells caused by pathogenic LRRK2.
Liu GH; Qu J; Suzuki K; Nivet E; Li M; Montserrat N; Yi F; Xu X; Ruiz S; Zhang W; Wagner U; Kim A; Ren B; Li Y; Goebl A; Kim J; Soligalla RD; Dubova I; Thompson J; Yates J; Esteban CR; Sancho-Martinez I; Izpisua Belmonte JC
Nature; 2012 Nov; 491(7425):603-7. PubMed ID: 23075850
[TBL] [Abstract][Full Text] [Related]
17. LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease.
Howlett EH; Jensen N; Belmonte F; Zafar F; Hu X; Kluss J; Schüle B; Kaufman BA; Greenamyre JT; Sanders LH
Hum Mol Genet; 2017 Nov; 26(22):4340-4351. PubMed ID: 28973664
[TBL] [Abstract][Full Text] [Related]
18. Decreased Sirtuin Deacetylase Activity in LRRK2 G2019S iPSC-Derived Dopaminergic Neurons.
Schwab AJ; Sison SL; Meade MR; Broniowska KA; Corbett JA; Ebert AD
Stem Cell Reports; 2017 Dec; 9(6):1839-1852. PubMed ID: 29129681
[TBL] [Abstract][Full Text] [Related]
19. RNA sequencing reveals MMP2 and TGFB1 downregulation in LRRK2 G2019S Parkinson's iPSC-derived astrocytes.
Booth HDE; Wessely F; Connor-Robson N; Rinaldi F; Vowles J; Browne C; Evetts SG; Hu MT; Cowley SA; Webber C; Wade-Martins R
Neurobiol Dis; 2019 Sep; 129():56-66. PubMed ID: 31085228
[TBL] [Abstract][Full Text] [Related]
20. Age at Onset of Parkinson's Disease Among Ashkenazi Jewish Patients: Contribution of Environmental Factors, LRRK2 p.G2019S and GBA p.N370S Mutations.
Yahalom G; Rigbi A; Israeli-Korn S; Krohn L; Rudakou U; Ruskey JA; Benshimol L; Tsafnat T; Gan-Or Z; Hassin-Baer S; Greenbaum L
J Parkinsons Dis; 2020; 10(3):1123-1132. PubMed ID: 32310186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
